Novo Nordisk and Valo Health Partner to Revolutionize Cardiometabolic Medication Development

In a groundbreaking collaboration, Novo Nordisk A/S and Valo Health, Inc. have joined forces to advance the development of innovative cardiometabolic disease medicines. Leveraging Valo's Opal Computational PlatformTM and extensive patient data, the partnership aims to usher in a new era of drug discovery in the realm of cardiovascular disorders.

The Opal Computational PlatformTM, a cutting-edge system developed by Valo, integrates real-world patient data, AI-powered small molecule discovery, and Biowire® human tissue modeling. This multifaceted approach accelerates the discovery and development process, propelling the field towards more effective and tailored treatments.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Valo's preclinical capabilities play a pivotal role in identifying, validating, and developing potential drug candidates. By targeting novel druggable pathways and predicting compound safety and efficacy, Valo's expertise offers a strategic advantage in the race for innovative cardiometabolic therapies.

As part of the agreement, Novo Nordisk gains access to three preclinical drug development programs focused on cardiovascular disorders, all conceived through the Opal Computational PlatformTM. The collaboration promises mutual benefits, with Valo set to receive an initial payment along with a potential near-term milestone payment of 60 million US dollars. Additional milestone payments for up to 11 programs, potentially totaling a staggering 2.7 billion dollars, further underscore the significance of this partnership. Research and development funds, as well as potential royalty payments, complete the extensive compensation structure.

Marcus Schindler, Executive Vice President and Chief Scientific Officer at Novo Nordisk, emphasized the transformative potential of artificial intelligence and machine learning in drug discovery. These technologies enable the early integration of human datasets, greatly enhancing our understanding of target biology. Schindler expressed enthusiasm for the innovative approach Valo employs, harnessing real-world human data to forge new pathways in cardiometabolic disease treatment.

The collaboration not only bolsters Novo Nordisk's technological capabilities but also expands the scope of their partnership with Valo. By combining their strengths in human data and genetics, the two companies aim to glean fresh insights into cardiovascular health. This collaborative effort promises to yield groundbreaking treatments for some of the most prevalent chronic diseases of our time.

David Berry, CEO and founder of Valo Health, hailed the partnership as a unique opportunity to propel the Opal Computational PlatformTM to new heights. The platform, which spans disease characterization to clinical development, represents a comprehensive solution for discovering and developing novel cardiometabolic therapies. Berry expressed eagerness to deliver innovative medicines to patients grappling with these pervasive chronic conditions.

With a shared commitment to innovation, the alliance is poised to make significant strides in addressing the complex challenges of cardiometabolic diseases.